Compare Enveric Biosciences Inc (ENVB) vs Koninklijke Philips NV (PHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Koninklijke Philips NV — how do they compare? Enveric Biosciences Inc trades at $1.4 (market cap $5.32M), while Koninklijke Philips NV trades at $27.22 (market cap $26.29B). The key difference: Koninklijke Philips NV is far larger — about 4941.7× Enveric Biosciences Inc's market cap, and Koninklijke Philips NV pays a 3.75% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | PHG | |
|---|---|---|
Market Cap | $5.32M | $26.29B |
Sector | Health | Health |
52-Week High | $17.40 | $32.91 |
52-Week Low | $1.28 | $24.38 |
Enterprise Value | $408.82K | $32.56B |
Dividend Yield | — | 3.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.38, up 4.55% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, though it beat EPS estimates in all four quarters. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies and positive preclinical results.
Outlook hinges on clinical progress, with 75% analyst buy ratings supporting potential upside, but high financial losses and negative ROE/ROA pose significant risks. Investors face volatility from regulatory developments and funding needs, making it speculative despite positive sentiment from recent operational updates.
PHG trades at $27.16, up 4.22% today. The stock shows mixed signals with a bearish technical outlook but improving fundamentals, including a return to profitability in 2025 with net income of $895 million. Recent news highlights AI integration in healthcare products and new FDA clearances, supporting growth initiatives. Analyst consensus is divided with 41% buy ratings amid neutral sentiment.
The outlook is cautiously optimistic given earnings recovery and strategic partnerships, but risks include high debt levels and competitive pressures. The stock presents a value opportunity if operational improvements continue, though technical weakness suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Koninklijke Philips NV
Philips is a diversified global healthcare company operating in three segments: diagnosis and treatment, connected care, and personal health. About 50% of the company's revenue comes from the diagnosis and treatment segment, which features imaging systems, ultrasound equipment, image-guided therapy solutions and healthcare informatics. The connected care segment (27% of revenue) encompasses monitoring and analytics systems for hospitals and sleep and respiratory care devices, whereas the personal health business (remainder of revenue) includes electric toothbrushes and men's grooming and personal-care products. In 2021, Philips generated EUR 17.2 billion in sales and had 80,000 employees in over 100 countries.
Read more on PHG →
